SHR: status-lymphoma
Viite: JCO, Vol 25, No 5 2007: pp. 579-586
|
Lyhenne |
Definition |
Nodal Masses |
Spleen, Liver |
0 |
Dg |
Diagnoosivaihe |
|
|
1 |
CR |
Disappearance of all evidence of disease |
FDG-PET negative; regression to normal size on CT |
Not palpable, nodules disappeared |
2 |
PR |
Regression of measuable disease and no new sites |
≥ 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes |
≥ 50% decrease in SPD of nodules ( |
3 |
SD |
Failure to attain CR/PR or PD |
(a) FDG-avid or PET positive prior to therapy; PET positive at prior sites of disease and no new sites on CT or PET |
|
4 |
Relapsed disease or PD |
Any new lesion or increase by ≥ 50% of previously involved sites from nadir |
Appearance of a new lesion(s) > 1.5 cm in any axis, ≥ 50% increase in SPD of more than one node, or ≥ 50% increase in longest diameter of a previously identifed node > 1 cm in short axis |
> 50% increase from nadir in the SPD of any previous lesions |
9 |
Relapsi (neuro) |
Isoloitu neurorelapsi |
|
|
90 |
Exitus-relapsi |
|
|
|
91 |
Exitus-infektio |
|
|
|
94 | Exitus - ei hoitoa | |||
95 |
Exitus, syy tuntematon |
|
|
|
999 |
Lost-to-follow-up |
|
|
|